Across TCGA pan-cancer cohorts, CTNS Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated CTNS data layer compared with 22 for mass-spec protein and 3 for mass-spec protein.
The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher CTNS Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated CTNS expression acts as an unfavorable survival marker.
BLCA, KIRC, and SCLC are the cancer types where CTNS Mutation most reproducibly stratifies survival.